A detailed history of Goldstein Advisors, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Goldstein Advisors, LLC holds 630 shares of LLY stock, worth $572,877. This represents 0.1% of its overall portfolio holdings.

Number of Shares
630
Previous 651 3.23%
Holding current value
$572,877
Previous $506 Million 12.62%
% of portfolio
0.1%
Previous 0.09%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 24, 2024

SELL
$724.87 - $909.04 $15,222 - $19,089
-21 Reduced 3.23%
630 $570 Million
Q1 2024

May 13, 2024

BUY
$592.2 - $792.28 $52,113 - $69,720
88 Added 15.63%
651 $506 Million
Q3 2023

Oct 18, 2023

BUY
$434.7 - $599.3 $13,910 - $19,177
32 Added 6.03%
563 $302 Million
Q2 2023

Jul 21, 2023

BUY
$350.74 - $468.98 $186,242 - $249,028
531 New
531 $249 Million
Q4 2022

Feb 03, 2023

BUY
$321.55 - $374.67 $193,894 - $225,926
603 New
603 $221 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $864B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Goldstein Advisors, LLC Portfolio

Follow Goldstein Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldstein Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Goldstein Advisors, LLC with notifications on news.